Möchten Sie immer auf dem neuesten Stand bleiben?

CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue of mitochondrial deficits in induced...

Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002)Average of 28% NfL...

SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...

First patient, first visit is planned for early June 2024Enrollment has been expanded by 80% to a maximum of 180 participants‘Real-world’ drug efficacy data will be collected by monitoring potential...

SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...

Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from...

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original...

Proprietary catalytic gold nanocrystals comprising Clene’s investigational drug CNM-Au8® develop a protein corona upon exposure to human blood plasma comprised of proteins that promote blood-brain...

Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label...

SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...